{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:29:31Z","timestamp":1762547371640,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rbmo.2024.104699","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:56:05Z","timestamp":1730742965000},"page":"104699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?"],"prefix":"10.1016","volume":"51","author":[{"given":"May-Tal","family":"Sauerbrun-Cutler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M","family":"Scarpaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.rbmo.2024.104699_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/deac145","article-title":"Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols","volume":"37","author":"Balkenende","year":"2022","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.rbmo.2024.104699_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/uog.17442","article-title":"Clomiphene citrate and letrozole to reduce follicle-stimulating hormone consumption during ovarian stimulation: systematic review and meta-analysis","volume":"50","author":"Bechtejew","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.rbmo.2024.104699_bib0003","first-page":"290","article-title":"A specific controlled ovarian stimulation (COS) protocol for fertility preservation in women with breast cancer undergoing neoadjuvant chemotherapy","volume":"21","author":"Cavagna","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"issue":"2","key":"10.1016\/j.rbmo.2024.104699_bib0004","first-page":"101","article-title":"Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT","volume":"15","author":"Ebrahimi","year":"2017","journal-title":"Int J Reprod Biomed"},{"issue":"1","key":"10.1016\/j.rbmo.2024.104699_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.fertnstert.2005.01.117","article-title":"The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study","volume":"84","author":"Garcia-Velasco","year":"2005","journal-title":"Fertil Steril"},{"issue":"10001","key":"10.1016\/j.rbmo.2024.104699_bib0006","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Group","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rbmo.2024.104699_bib0007","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.fertnstert.2003.03.001","article-title":"Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination","volume":"80","author":"Healey","year":"2003","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.rbmo.2024.104699_bib0008","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5468\/ogs.2014.57.3.216","article-title":"The effect of aromatase inhibitor letrozole incorporated in gonadotrophin-releasing hormone antagonist multiple dose protocol in poor responders undergoing in vitro fertilization","volume":"57","author":"Lee","year":"2014","journal-title":"Obstet Gynecol Sci"},{"issue":"2","key":"10.1016\/j.rbmo.2024.104699_bib0009","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.fertnstert.2014.05.017","article-title":"Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies","volume":"102","author":"Meirow","year":"2014","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.rbmo.2024.104699_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/13543784.12.3.353","article-title":"Aromatase inhibitors for the treatment of infertility","volume":"12","author":"Mitwally","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.rbmo.2024.104699_bib0011","first-page":"653","article-title":"Letrozole as co-treatment agent in ovarian stimulation antagonist protocol in poor responders: A double-blind randomized clinical trial","volume":"17","author":"Moini","year":"2019","journal-title":"Int J Reprod Biomed"},{"issue":"1","key":"10.1016\/j.rbmo.2024.104699_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/humrep\/deg045","article-title":"Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen","volume":"18","author":"Oktay","year":"2003","journal-title":"Hum Reprod"},{"issue":"19","key":"10.1016\/j.rbmo.2024.104699_bib0013","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1200\/JCO.2005.05.037","article-title":"Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation","volume":"23","author":"Oktay","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.rbmo.2024.104699_bib0014","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.rbmo.2024.104699_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/09513590.2016.1177013","article-title":"Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes\u2020","volume":"32","author":"Pereira","year":"2016","journal-title":"Gynecol Endocrinol"},{"issue":"8","key":"10.1016\/j.rbmo.2024.104699_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jogoh.2021.102139","article-title":"Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysis","volume":"50","author":"Qin","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"5","key":"10.1016\/j.rbmo.2024.104699_bib0017","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/humrep\/dex027","article-title":"The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review","volume":"32","author":"Rodgers","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.rbmo.2024.104699_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejmech.2019.05.023","article-title":"Estrogen signaling: An emanating therapeutic target for breast cancer treatment","volume":"177","author":"Saha","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.rbmo.2024.104699_bib0019","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13048-020-00666-z","article-title":"Does daily co administration of gonadotropins and letrozole during the ovarian stimulation improve IVF outcome for poor and sub optimal responders?","volume":"13","author":"Shapira","year":"2020","journal-title":"J Ovarian Res"},{"issue":"3","key":"10.1016\/j.rbmo.2024.104699_bib0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10815-020-02030-y","article-title":"Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients","volume":"38","author":"Shulman","year":"2021","journal-title":"J Assist Reprod Genet"},{"issue":"24","key":"10.1016\/j.rbmo.2024.104699_bib0021","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648324008885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648324008885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:24:19Z","timestamp":1762547059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648324008885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1472648324008885"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2024.104699","relation":{},"ISSN":["1472-6483"],"issn-type":[{"type":"print","value":"1472-6483"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2024.104699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104699"}}